Incyte Corporation (INCY) Shares are Up 5.97%

Incyte Corporation (INCY) : Traders are bullish on Incyte Corporation (INCY) as it has outperformed the S&P 500 by a wide margin of 15.58% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.79%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 5.97% in the last 1 week, and is up 14.96% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 11.62% and the 50-Day Moving Average is 11.9%.The 200 Day SMA reached 16.75%

Incyte

Incyte Corporation (NASDAQ:INCY): After opening at $92.71, the stock dipped to an intraday low of $90.57 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $94.66 and the buying power remained strong till the end. The stock closed at $94.29 for the day, a gain of 2.17% for the day session. The total traded volume was 1,707,564. The stocks close on the previous trading day was $94.29.

Incyte Corporation (INCY) : The most positive equity analysts on Incyte Corporation (INCY) expects the shares to touch $135, whereas, the least positive believes that the stock will trade at $92 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $102.42 with an expected fluctuation of $12.12 from the mean.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.